Molecular therapeutic approaches for pediatric acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

http://www.wikidata.org/entity/Q37643136

about

Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.Frequency of 11q23/MLL gene rearrangement in Egyptian childhood acute myeloblastic leukemia: Biologic and clinical significance.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.PAN3-PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia.

P2860

Q35687836-CE346E8B-C410-432F-9C4E-7B34DC499AAF Q36053792-DA6B538E-CB02-4AF9-9875-F7B5271093EE Q41298278-4495D88A-064F-4EE4-88B7-81EF36EE2FF0 Q43012375-F7134A25-66A6-422D-A928-E11281CCE363 Q47136441-31ADC962-80FA-4632-A80E-65F57BDF5543 Q49207324-14E71A7D-E1A2-49F0-BC4B-203882119987 Q51000809-BB9D0747-5F86-4567-BE76-F0D2F1B5272B Q52348448-B932F5DD-BB38-4DF6-85DB-2DD8731F607A

P2860

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

http://www.wikidata.org/entity/Q37643136

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@en

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@nl

type

label

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@en

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@nl

prefLabel

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@en

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@nl

P1433

Q37643136-0D5CCD40-5F62-4912-B456-049ECE16ACB5

P1476

Q37643136-129DCB73-128D-445E-B278-AC96CC5B6BCB

P2093

Q37643136-38E92887-ABBF-4045-A1A5-CF7D3D204D47

Q37643136-D85BC4BB-BBE1-4861-8034-D8D53891EE29

P2860

Q37643136-01E26B5E-467B-415E-8437-CE05AABB92E5

Q37643136-0234E47C-CECF-47E9-822D-40C9A3BC8D2F

Q37643136-0567B785-ADE0-40A4-A8FB-37FFDA0212E4

Q37643136-0BF2EAFA-13DD-418A-B67B-747D11BA748B

Q37643136-10135488-30CE-4DF9-B195-C57DF0376362

Q37643136-112CCC19-862F-4D2E-925C-0BB3F6DBBBF6

Q37643136-1532FCF6-2EF6-4059-BD80-B064F52C0E28

Q37643136-16BC4CCA-E73F-476B-8C0A-200E37AC0F25

Q37643136-197B0104-3573-4652-8AA6-BED48E256286

Q37643136-1984AF8B-F68B-455E-9C5E-4DC118704EC3

P304

Q37643136-359A30B2-990B-4FC4-900A-4E4A4D0AC402

P31

Q37643136-B2A73D45-F274-4FC2-9291-E0E0616D31A3

P356

Q37643136-827AF3C0-981C-48C3-8CBF-E5D94CE39FFA

P478

Q37643136-EDDF6BFA-8369-46B5-B64A-4E78AEB3BE99

P50

Q37643136-3AC98302-EF7D-4FCC-9945-E821516153B0

P577

Q37643136-FF755596-2375-4FAE-A1C2-837BF5F4B40C

P5875

Q37643136-BA27907C-6C2C-4F99-A362-26F1674F6EB8

P698

Q37643136-DDB95721-1D49-4A88-8BDA-82C48BAEDC47

P921

Q37643136-686D8018-C991-4302-ABF4-612AA4DCAE5E

P932

Q37643136-02B92220-BAD8-4131-8331-D71E22B41429

P356

FONC.2014.00055

P1433

Frontiers in Oncology

P1476

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

@en

P2093

Jessica A Pollard

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

P2860

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia

Chimeric antigen receptor therapy for cancer

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

P304

55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00055

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Sarah K. Tasian

P577

2014-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261141049

http://www.w3.org/2001/XMLSchema#string

P698

24672775

http://www.w3.org/2001/XMLSchema#string

P921

P932

3957536

http://www.w3.org/2001/XMLSchema#string